# CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma

> **NCT06850285** · NA · RECRUITING · sponsor: **Shanxi Bethune Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Lymphoma, B-Cell

## Interventions

- **DRUG:** chimeric antigen receptor gene modified T cells

## Key facts

- **NCT ID:** NCT06850285
- **Lead sponsor:** Shanxi Bethune Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-05
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850285, "CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06850285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*